Infectious diseases remain a defining pressure on global healthcare systems — yet the diagnostic landscape looks unrecognizable from one region to the next.
High-income economies are fighting to curb antimicrobial resistance (AMR) and ease emergency department overload. Low- and middle-income regions are still building basic laboratory infrastructure and combating endemic disease burdens.
No single diagnostic platform can solve both sets of challenges with the same configuration. Below is a breakdown of unmet clinical needs across developed and emerging markets — and how next-generation Molecular Point-of-Care (mPOCT) technology is evolving to close these gaps.
1. Developed Markets: Precision, Speed, and Antimicrobial Stewardship
In mature healthcare systems, the priority is elevating clinical outcomes and operational efficiency within already established lab networks.
Inpatient & Critical Care: Racing Against Time and Resistance
For severe infections such as hospital-acquired pneumonia, sepsis, and bacterial meningitis, every hour of delayed targeted therapy directly raises mortality risk. Traditional culture-based diagnostics take 24–72 hours, leaving clinicians with no option but broad-spectrum empirical antibiotic use — a major driver of AMR.
What tertiary care settings urgently need is deep multiplexing capability: the ability to simultaneously identify dozens of viral, bacterial, and fungal pathogens, plus key antimicrobial resistance markers, directly from raw patient specimens.
Outpatient & Emergency Triage: Faster Decisions, Better Throughput
ED overcrowding is a systemic operational and clinical risk. Frontline clinicians need actionable results within a standard consultation window (30–45 minutes) to distinguish viral from bacterial causes of respiratory and gastrointestinal infections.
Faster, on-site molecular testing reduces unnecessary antibiotic prescriptions, avoids preventable admissions, and accelerates bed turnover — delivering both clinical and economic value.
2. Emerging Markets: Diagnostic Equity, Public Health, and Primary Care
In developing healthcare ecosystems, the challenge shifts from optimizing existing systems to building accessible diagnostic capacity where it barely exists.
Closing the "Lab Desert" in Primary Care
Conventional qPCR testing requires BSL-2 laboratory facilities, capital equipment, and specially trained technicians — resources rarely available at community clinics and rural health centers. As a result, most patients receive empirical treatment, leading to misdiagnosis, delayed care, and unnecessary antibiotic exposure.
There is an urgent need for sample-in, result-out platforms that deliver accurate nucleic acid testing without complex infrastructure or specialized personnel.
Vector-Borne & Endemic Disease Control
Regions burdened by arboviruses (dengue, Zika, chikungunya) and malaria need decentralized, rapid screening tools. Deploying molecular diagnostics at the community level enables public health authorities to detect and contain outbreaks earlier, before they escalate into regional public health crises.
3. The Molecular POCT Paradigm: Built for Dual Market Realities
How can one technology category serve both an intensive care unit in Europe and a remote clinic in Southeast Asia or Latin America?
The answer lies in flexible, microfluidic-based syndromic testing platforms.
Modern microfluidic chip technology has broken the historical trade-off between multiplex capacity, speed, and ease of use. By adapting hardware design and assay panel menus to local needs, mPOCT can deliver tailored value across very different care settings:
For high-throughput inpatient care: Multi-sample, high-multiplex platforms running 25+ targets (including AMR markers) per run give ICU teams the granular pathogen data required for precision antimicrobial stewardship.
For decentralized and primary care: Ultra-compact, modular units with wireless scalability deliver 10–16 target syndromic panels in under 45 minutes, bringing central-lab accuracy directly to the point of care.
Redefining Molecular Accessibility
At Chenghui Medical, we design our technology around the healthcare ecosystem — not the other way around.
Our microfluidic molecular POCT portfolio addresses both ends of the global diagnostic spectrum: the Multi-Disc (CQ-0404) system for high-complexity, multi-sample critical care testing, and the Flex-Disc (CH-0104) modular platform for rapid, decentralized primary care and emergency use.
Together, they help providers worldwide deliver precise, syndromic diagnostic answers — wherever patients need them most.
#MolecularDiagnostics #POCT #InfectiousDiseases #AntimicrobialStewardship #GlobalHealth #IVD #Microfluidics #PublicHealth